WO2012106473A3 - Dosing for treatment with anti-egfl7 antibodies - Google Patents

Dosing for treatment with anti-egfl7 antibodies Download PDF

Info

Publication number
WO2012106473A3
WO2012106473A3 PCT/US2012/023547 US2012023547W WO2012106473A3 WO 2012106473 A3 WO2012106473 A3 WO 2012106473A3 US 2012023547 W US2012023547 W US 2012023547W WO 2012106473 A3 WO2012106473 A3 WO 2012106473A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosing
treatment
egfl7 antibodies
egfl7
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/023547
Other languages
French (fr)
Other versions
WO2012106473A2 (en
WO2012106473A8 (en
Inventor
Shuang BAI
Daniel S. Chen
Roel Funke
Priti Hegde
Louie NAUMOVSKI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Genentech Inc
Original Assignee
F Hoffmann La Roche AG
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Genentech Inc filed Critical F Hoffmann La Roche AG
Priority to RU2013140471/15A priority Critical patent/RU2013140471A/en
Priority to BR112013019080A priority patent/BR112013019080A2/en
Priority to MX2013008922A priority patent/MX2013008922A/en
Priority to JP2013552611A priority patent/JP2014510044A/en
Priority to KR1020137023038A priority patent/KR20140012080A/en
Priority to CN2012800151104A priority patent/CN103476430A/en
Priority to CA2825969A priority patent/CA2825969A1/en
Priority to EP12742541.1A priority patent/EP2670437A2/en
Publication of WO2012106473A2 publication Critical patent/WO2012106473A2/en
Publication of WO2012106473A3 publication Critical patent/WO2012106473A3/en
Publication of WO2012106473A8 publication Critical patent/WO2012106473A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention concerns dosing of anti-EGFL7 antibodies for cancer therapy.
PCT/US2012/023547 2011-02-02 2012-02-01 Dosing for treatment with anti-egfl7 antibodies Ceased WO2012106473A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
RU2013140471/15A RU2013140471A (en) 2011-02-02 2012-02-01 DOSING FOR TREATMENT BY ANTIBODIES AGAINST EGFL7
BR112013019080A BR112013019080A2 (en) 2011-02-02 2012-02-01 methods for treating cancer, nsclc and colorectal cancer in a human patient and article of manufacture
MX2013008922A MX2013008922A (en) 2011-02-02 2012-02-01 Dosing for treatment with anti-egfl7 antibodies.
JP2013552611A JP2014510044A (en) 2011-02-02 2012-02-01 Administration for treatment with anti-EGFL7 antibody
KR1020137023038A KR20140012080A (en) 2011-02-02 2012-02-01 Dosing for treatment with anti-egfl7 antibodies
CN2012800151104A CN103476430A (en) 2011-02-02 2012-02-01 Dosing for treatment with anti-EGFl7 antibodies
CA2825969A CA2825969A1 (en) 2011-02-02 2012-02-01 Dosing for treatment with anti-egfl7 antibodies
EP12742541.1A EP2670437A2 (en) 2011-02-02 2012-02-01 Dosing for treatment with anti-egfl7 antibodies

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161438944P 2011-02-02 2011-02-02
US61/438,944 2011-02-02
US201161492743P 2011-06-02 2011-06-02
US61/492,743 2011-06-02
US201261587382P 2012-01-17 2012-01-17
US61/587,382 2012-01-17

Publications (3)

Publication Number Publication Date
WO2012106473A2 WO2012106473A2 (en) 2012-08-09
WO2012106473A3 true WO2012106473A3 (en) 2012-11-01
WO2012106473A8 WO2012106473A8 (en) 2013-06-06

Family

ID=46603300

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/023547 Ceased WO2012106473A2 (en) 2011-02-02 2012-02-01 Dosing for treatment with anti-egfl7 antibodies

Country Status (11)

Country Link
US (1) US20130004498A1 (en)
EP (1) EP2670437A2 (en)
JP (1) JP2014510044A (en)
KR (1) KR20140012080A (en)
CN (1) CN103476430A (en)
AR (1) AR085105A1 (en)
BR (1) BR112013019080A2 (en)
CA (1) CA2825969A1 (en)
MX (1) MX2013008922A (en)
RU (1) RU2013140471A (en)
WO (1) WO2012106473A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX358254B (en) 2011-09-02 2018-08-10 Syndax Pharmaceuticals Inc Methods for the treatment of breast cancer.
US20160046715A1 (en) * 2013-05-17 2016-02-18 Abwiz Bio, Inc. T regulatory cells and uses thereof
US11702469B2 (en) 2017-04-24 2023-07-18 Ohio State Innovation Foundation Recombinant EGFL7, EGFL7 antibodies, and uses thereof
WO2019112958A1 (en) * 2017-12-05 2019-06-13 Abbvie Biotherapeutics Inc. Abt-165 in combination with folinic acid, 5-fluorouracil, and irinotecan for the treatment of cancers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100203041A1 (en) * 2006-03-16 2010-08-12 Genentech , Inc. Antibodies to egfl7 and methods for their use
US20100285009A1 (en) * 2009-05-08 2010-11-11 Genentech, Inc. Humanized anti-egfl7 antibodies and methods using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100203041A1 (en) * 2006-03-16 2010-08-12 Genentech , Inc. Antibodies to egfl7 and methods for their use
US20100285009A1 (en) * 2009-05-08 2010-11-11 Genentech, Inc. Humanized anti-egfl7 antibodies and methods using same

Also Published As

Publication number Publication date
EP2670437A2 (en) 2013-12-11
CN103476430A (en) 2013-12-25
JP2014510044A (en) 2014-04-24
MX2013008922A (en) 2013-10-01
AR085105A1 (en) 2013-09-11
CA2825969A1 (en) 2012-08-09
RU2013140471A (en) 2015-03-10
BR112013019080A2 (en) 2019-06-11
WO2012106473A2 (en) 2012-08-09
KR20140012080A (en) 2014-01-29
WO2012106473A8 (en) 2013-06-06
US20130004498A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
IL279330A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
IL276434A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2013114367A8 (en) C10rf32 antibodies, and uses thereof for treatment of cancer
IL239981A0 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
IL240060A0 (en) Therapy involving antibodies against claudin 18.2 for treatment of cancer
SMT201700387T1 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
SMT202200458T1 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
ZA201306807B (en) Anti-alpha-v integrin antibody for the treatment of prostate cancer
PL2976360T3 (en) Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2012106473A8 (en) Dosing for treatment with anti-egfl7 antibodies
IL232339A0 (en) C10rf32 antibodies , and uses thereof for treatment of cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12742541

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2825969

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2013552611

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2012742541

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/008922

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20137023038

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013140471

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013019080

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112013019080

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130725